Cite
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
MLA
Sehgal, Alison, et al. “Lisocabtagene Maraleucel as Second-Line Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma Who Were Not Intended for Haematopoietic Stem Cell Transplantation (PILOT): An Open-Label, Phase 2 Study.” Lancet Oncology, vol. 23, no. 8, Aug. 2022, pp. 1066–77. EBSCOhost, https://doi.org/10.1016/S1470-2045(22)00339-4.
APA
Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, R., Licitra, E., Fanning, S., Gupta, N., Dubowy, R., D’Andrea, A., Wang, L., & Ogasawara, K. (2022). Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncology, 23(8), 1066–1077. https://doi.org/10.1016/S1470-2045(22)00339-4
Chicago
Sehgal, Alison, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, et al. 2022. “Lisocabtagene Maraleucel as Second-Line Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma Who Were Not Intended for Haematopoietic Stem Cell Transplantation (PILOT): An Open-Label, Phase 2 Study.” Lancet Oncology 23 (8): 1066–77. doi:10.1016/S1470-2045(22)00339-4.